Literature DB >> 11607933

Different ligands-different receptor conformations: modeling of the hER alpha LBD in complex with agonists and antagonists.

U Egner1, N Heinrich, M Ruff, M Gangloff, A Mueller-Fahrnow, J M Wurtz.   

Abstract

The aim of this study is to compare crystal structures of nuclear receptor ligand binding domains in complex with different agonists and partial agonists to achieve a better understanding of the three-dimensional structures and their ligand-induced conformational changes. This led to the identification of structurally conserved "rigid" regions and more flexible parts of the proteins. The analysis was found to be of great value in fitting selected non-steroidal compounds into the human estrogen receptor alpha (hER alpha) ligand binding pocket. The experimentally determined binding affinities for a number of 2-aryl indoles and 2-aryl indenones are in good agreement with the subsequently modeled binding interactions. To date, no crystal structure is published for a complex with a pure antagonist. We therefore used the available structural information on complexes with partial agonists and the crystal structure of a mutant protein in complex with estradiol displaying a similar conformation to predict binding interactions for antagonists. The results are discussed in detail. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607933     DOI: 10.1002/med.1024

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  8 in total

1.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

2.  Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.

Authors:  Yuan-Shan Zhu; Li-Qun Cai; Ying Huang; Jason Fish; Lu Wang; Zhi-Kai Zhang; Julianne L Imperato-McGinley
Journal:  J Androl       Date:  2005 Jul-Aug

3.  Inhibition of serotonin re-uptake by licorice constituents.

Authors:  Rivka Ofir; Snait Tamir; Soliman Khatib; Jacob Vaya
Journal:  J Mol Neurosci       Date:  2003-04       Impact factor: 3.444

4.  Structure of estradiol metal chelate and estrogen receptor complex: the basis for designing a new class of selective estrogen receptor modulators.

Authors:  Min-Jun Li; Harry M Greenblatt; Orly Dym; Shira Albeck; Adi Pais; Chidambaram Gunanathan; David Milstein; Hadassa Degani; Joel L Sussman
Journal:  J Med Chem       Date:  2011-04-19       Impact factor: 7.446

5.  Binding mode of ecdysone agonists to the receptor: comparative modeling and docking studies.

Authors:  Atsushi Kasuya; Yoshihiro Sawada; Yoshihisa Tsukamoto; Keiji Tanaka; Tetsuya Toya; Mikio Yanagi
Journal:  J Mol Model       Date:  2003-01-14       Impact factor: 1.810

6.  Foxl2, a forkhead transcription factor, modulates nonclassical activity of the estrogen receptor-alpha.

Authors:  So-Youn Kim; Jeffrey Weiss; Minghan Tong; Monica M Laronda; Eun-Jig Lee; J Larry Jameson
Journal:  Endocrinology       Date:  2009-09-24       Impact factor: 4.736

7.  Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer.

Authors:  Amneh Shtaiwi; Rohana Adnan; Melati Khairuddean; Shafi Ullah Khan
Journal:  RSC Adv       Date:  2019-11-01       Impact factor: 4.036

8.  Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.

Authors:  Adi Pais; Hadassa Degani
Journal:  Front Oncol       Date:  2016-04-27       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.